Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: SC Advanced prostate carcinoma Initial: 500 mcg 8 hrly for 7 days. Maintenance: 200 mcg once daily. Depot 6.3 mg implant 8 wkly or 9.45 mg 12 wkly. Pituitary desensitisation before ovulation induction w/ gonadotrophins 200-500 mcg/day until pituitary downregulation occurs, usually for 1-3 wk. Nasal Endometriosis 150 mcg into each nostril 3 times/day for about 6 mth. Pituitary desensitisation before ovulation induction w/ gonadotrophins 150 mcg 4 times/day beginning on day 1 or day 21 of the menstrual cycle until pituitary downregulation occurs, usually for 1-3 wk.
Hormone-dependent tumors. Pituitary adenoma, weight-related amenorrhoea.
Special Precautions
Hypertension, diabetes, depression, polycystic ovarian disease. Avoid use of nasal decongestants before and at least 30 min after treatment. Men at risk from tumor flare. Pregnancy and lactation.
Adverse Reactions
GI disturbances, headache/lightheadedness, increase in menstrual bleeding, mood changes, nervousness, palpitations, acne, dry skin, decreased glucose tolerance, changes in scalp and body hair, ovarian hyperstimulation, reactions or pain at site of injection, thrombophloebitis, swelling, pruritus, hypersensitivity reactions, tumor flare (may manifest as increase in bone pain), spinal cord compression, worsening of urinary tract symptoms with hematuria and urinary obstruction, vag dryness, hot flushes, loss of libido, osteoporosis. In men, hot flushes, breast swelling, tenderness and sexual dysfunction.
Drug Interactions
Drugs affecting pituitary secretion of gonadotrophins, hormonal therapy and corticosteroids may alter the response. Spironolactone and levodopa can stimulate secretion of gonadotrophins. Phenothiazines, dopamine antagonists, digoxin and sex hormones can inhibit gonadotrophin secretion.
ATC Classification
L02AE01 - buserelin ; Belongs to the class of gonadotropin releasing hormone analogues. Used in endocrine therapy.
Disclaimer: This information is independently developed by CIMS based on buserelin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in